NasdaqGM:MNKDBiotechs
A Look At MannKind (MNKD) Valuation After New United Therapeutics Inhaler Raises Royalty Concerns
MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile.
See our latest analysis for MannKind.
The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...